Research Nester released a report titled “RNAi Technology Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global RNAi technology market in terms of market segmentation by therapy area, by application and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
RNA interference technology involves the use of ribonucleic acids for the inhibition of gene expression. This technique is being developed for use in the field of medicine in order to develop therapeutics that target specific genes and help with the treatment of various disorders. The market for RNA interference technology is projected to grow by a CAGR of about 15% during the forecast period, i.e., 2019-2027. The market is segmented by therapy area, by application and by region, out of which, the therapy area segment is further segmented into cancer, liver disorders, respiratory disorders, neurological disorders, autoimmune disorders and others. Out of these, the cancer segment is estimated to observe augmented growth in the market as a result of rising cases of cancer and a growing demand for effective cancer therapies.
The RNA interference technology market in North America is anticipated to hold the leading share on account of presence of leading companies in the region, mainly in the United States, as well as the growing research activities by these companies for the development of effective therapeutics using RNAi technology. Rising prevalence of cancer and related disorders in the region is further estimated to contribute towards the market growth. The market in Asia Pacific is predicted to grow at the highest rate over the forecast period on the back of growing awareness among people about the risks associated with various disorders and the increasing funding towards the research and development activities in the healthcare sector in the region.
Technological Advancements in the Medical Sector to Boost the Market Growth
The application of RNA interference technology in oncology, liver disorders, respiratory disorders, autoimmune disorders, ocular disorders and others is anticipated to increase the scope of its usage in various branches of medicine. This is estimated to significantly impact the market growth globally over the forecast period. However, the strict government policies and FDA regulations for the approval of drugs and therapies is estimated to hamper the market growth significantly in the upcoming years.
This report also provides the existing competitive scenario of some of the key players of the global RNAi technology market which includes company profiling of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Quark Pharmaceuticals, Inc., Arbutus Biopharma (NASDAQ: ABUS), Benitec Biopharma (ASX: BLT), Calando, Silence Therapeutics (LON: SLN) and Gotham Therapeutics. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global RNAi technology market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.